KARYOPHARM THERAPEUTICS INC(NASDAQ:KPTI) stock News

KPTI Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Benzinga - Mentions: CALC CAPR ATHE MIST ...

12 Health Care Stocks Moving In Friday's Intraday Session

9 days ago - By: Benzinga - Mentions: TXMD CAPR WINT DARE ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

19 days ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Present at the Jefferies Global Healthcare Conference

2 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Zacks Investment Research

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

2 months ago - By: Zacks Investment Research

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

2 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

2 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

2 months ago - By: Zacks Investment Research - Mentions: OPTN

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

2 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

2 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

3 months ago - By: Zacks Investment Research - Mentions: NBIX

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

3 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Antengene Corporation Limited

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

5 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Announces 1-for-15 Reverse Stock Split

5 months ago - By: The Motley Fool

Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript

5 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

5 months ago - By: Antengene Corporation Limited

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

6 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

7 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

7 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

8 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

8 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

8 months ago - By: Karyopharm Therapeutics Inc.

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

9 months ago - By: Antengene Corporation Limited

KARYOPHARM THERAPEUTICS INC (KPTI) Stock News

KPTI Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Present at the Jefferies Global Healthcare Conference

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024